Compare BioNano Genomics Inc (BNGO) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Norwegian Cruise Line Holdings Ltd trades at $19.89 (market cap $8.93B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 676.5× BioNano Genomics Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | NCLH | |
|---|---|---|
Market Cap | $13.20M | $8.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $26.94 |
52-Week Low | $1.09 | $14.79 |
Enterprise Value | $15.81M | $23.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Norwegian Cruise Line Holdings (NCLH) trades at $19.63, up 0.1% on the day, with a neutral technical signal and strong analyst consensus. Recent earnings beats and a 55.55% buy rating from analysts support optimism, though the stock faces headwinds from high debt levels and volatile cash flows. Revenue growth has improved from $4.8B in 2022 to $9.83B in 2025, but net margins remain modest at 4.3%.
The outlook is cautiously positive, with a consensus price target of $21.71 offering ~11% upside. Key opportunities include falling energy costs and robust booking trends, while risks involve elevated leverage and macroeconomic sensitivity. Investors should weigh solid fundamentals against balance sheet constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
